ArticleBrain and behavior2025
The Effect of Acylcarnitines on Cognitive Function: A Two-Sample Mendelian Randomization Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveClinical trials investigating the association between acylcarnitines and cognitive function have yielded conflicting results. We conducted a Mendelian randomization (MR) study to examine the causal associations between 20 acylcarnitines and neurocognitive outcomes.
methodsSingle-nucleotide polymorphisms of 20 acylcarnitines were extracted from primary European ancestry-based genome-wide association studies. Two-sample MR (TSMR) was performed to initially screen for acylcarnitines potentially associated with cognitive performance. Further TSMR analysis was conducted to investigate the associations between specific acylcarnitines and other cognitive outcomes, dementia, and brain structure.
resultsAmong the 20 acylcarnitines, we observed that lower genetically predicted levels of butyrylcarnitine (β = -0.06, 95% CI: [-0.11 to -0.02], p = 0.003) and acetyl-L-carnitine (β = -0.02, 95% CI: [-0.04 to 0], p = 0.04) were associated with adverse neurocognitive effects. Furthermore, we found a negative correlation between low genetically predicted levels of butyrylcarnitine and cognitive function (β = -0.17, 95% CI: [-0.3 to -0.05], p = 0.01) as well as intelligence (β = -0.05, 95% CI: [-0.09 to -0.02], p = 0.003). However, there was no evidence supporting any association between these two acylcarnitines and dementia or brain structure.
conclusionsOur results suggest a causal association between acetyl-L-carnitine and butyrylcarnitine levels and adverse neurocognitive effects. Multicenter, multiregional, and large sample studies are needed to further validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.